Pronunciation:(nih-nal-teen-uh-teen) (nih-nal-teenuh-teen)
A new aromatase inhibitor, arimidex (1 mg, 1.25 mg and 3.5 mg), is licensed for the treatment of early breast cancer in postmenopausal women (aged between 35 and 55 years) in the UK. The drug is being investigated for its efficacy in hormone receptor-positive (HR+) breast cancer and for its potential to reduce the risk of breast cancer recurrence. The study was designed to compare the efficacy of 1 mg and 3.5 mg of arimidex to tamoxifen (NCT 00766001), anastrozole (NCT 01182988), and the combination drug tamoxifen and letrozole (NCT 01984518). A comparison was also done among the two drug groups. The objective of this study was to compare the efficacy of the two drug groups in the treatment of HR+ early breast cancer.
Patients with a positive HER2 receptor positive (HR+) breast cancer treated with tamoxifen and arimidex (NCT 01782895), were included. Patients with ER+ breast cancer (n=5) and HER2-positive breast cancer (n=5) were excluded.
Time to distant recurrence and survival were analyzed. The primary end point was the response rate. Secondary end points were the proportion of patients who had a complete response and the rate of adverse events.
The median age was 55 years with a median age range of 50-70 years.
Overall, the median follow-up time was 21 months (range: 3-42 months). Patients with anastrozole (NCT 01224545), tamoxifen (NCT 00766001), and the combination drug tamoxifen and letrozole (NCT 01984518) had a significantly better survival rate compared with the other group (p<0.01).
A total of 295 (54%) patients were included in the analysis.
Patients were divided into two groups based on the group of patients with anastrozole: Arimidex (n=47) and tamoxifen (NCT 01782895).
Patients with HR+ breast cancer (n=5) and HR+ HER2-positive breast cancer (n=5) were excluded. The median age at the time of enrollment was 47 years (range: 25-65).
There was a significant difference between the two groups in the proportion of patients who had a complete response (p<0.001) and a low risk of adverse effects (p<0.05).
Time to distant recurrence and survival were compared between the two groups (p<0.01).
A total of 295 (54%) patients were enrolled in the study.
The median follow-up time was 21 months (range: 3-42 months). The patients who died, because of post-adverse events, had a significantly longer median time to distant recurrence (p<0.01).
A total of 295 (54%) patients were enrolled.
Product name:ARIMIDEX 10 MG
Company name:
DIN:03572929
Status:Case
Status date:2017-02-01
| Active ingredient(s) | Strength |
|---|---|
| Arimidex (10 MG) | 1mg |
Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.
For consumers| Resource | Description |
|---|---|
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections:
| |
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are:
|
Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals. |
| After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes. |
The Arimidex Canada Drug Pipeline List is a comprehensive guide that evaluates the top Canadian online pharmacies and pharmaceutical companies for Arimidex Canada Drug Pipeline Services. By reading this article, you can make an informed decision about whether you are a Canadian, looking for reliable sources to obtain the Arimidex Canada Drug Pipeline List.
The Arimidex Canada Drug Pipeline List is a comprehensive guide that evaluates the top UK online pharmacies and pharmaceutical companies for Arimidex Canada Drug Pipeline Services.
The Arimidex Canada Drug Pipeline List is a comprehensive guide that evaluates the top Canada online pharmacies and pharmaceutical companies for Arimidex Canada Drug Pipeline Services.
The Arimidex Canada Drug Pipeline List is a comprehensive guide that evaluates the top Australia online pharmacies and pharmaceutical companies for Arimidex Canada Drug Pipeline Services.
Arimidex 1mg tablet is an anticancer drug with the ingredient Anastrozole. It belongs to the medication class known as aromatase inhibitors. The Arimidex tablet is used to treat hormone-dependent breast cancer in postmenopausal women. Aromatase inhibitors reduce estrogen levels by preventing an enzyme in adipose tissue from converting other hormones into estrogen. This medication helps to delay the recurrence of early-stage breast cancer.
The common side effects are nausea, vomiting, loss of appetite, fever, itching, inflammation of the joints (arthritis), bone loss (osteoporosis), bleeding from the vagina, hypersensitivity, and joint, stomach, and kidney pain.
If you are allergic to Anastrozole or its ingredients, tell your doctor before starting treatment with this medication. Tell your doctor if you are still experiencing menstruation and have not yet reached menopause, have osteoporosis, or have any liver or kidney problems. If you are lactose intolerant, consult your doctor before taking this medicine. Do not take medicine if you are pregnant or breastfeeding.
How common is the diagnosis of breast cancer?A breast cancer diagnosis can range from as little as 1 year up to 5 years. If you have already been diagnosed with breast cancer in the past 5 years, your doctor may increase the number of tests done to check your risk of developing it. If you do not have any other signs of breast cancer, your doctor may stop treatment with Anastrozole and a mammogram (3-4 x 3-4 X 3-4 Expected values) may be done.
How do I take the acne drug?To treat acne, the acne drug may take a few weeks to show results. Take Anastrozole on an empty stomach for best results. If it has not worked for you after 3-4 days, speak to your doctor. You may take the acne drug for a few months. If it has not worked for you after 5-7 days, speak to your doctor. If it has not worked for you after 7 days, speak to your doctor. If it has not worked for you after 8 days, speak to your doctor. You should talk to your doctor if you take the acne drug for more than 7 days or more often than once a week.
Missed or missing out on a dose?Take your medicine at least 24 hours before or after missing a dose. If you take a double dose of Anastrozole, you may get an extra side effect, such as liver damage or kidney damage. If you miss a dose, do not take it. If you take a missed dose, do not take it.
How long does it take for the drug to work?The onset of action for the acne drug may vary depending on the specific side effect and your body’s response. However, it usually takes 2-3 weeks for most acne drugs to show their full effect. If you take more acne drugs than normal, your doctor may change your dosage slightly.
If you take too much of the acne drug, symptoms may include acne breakouts, facial flushing, headache, nausea, breast pain, and bone density loss. You may also need to take different medicines to treat your acne.
How do I store the drug?Store the drug in a cool, dry place away from direct sunlight. Keep it out of the reach of children and pets. Do not refrigerate, and keep all medicines out of the reach of pets and children.
What is the active ingredient in the drug?The active ingredient in the drug is Anastrozole. It works by blocking the effects of estrogen on the body. Estrogen causes changes to the body's mammary tissue, which stop the growth of breast cancer cells. Arimidex 1mg tablet belongs to the aromatase inhibitors class of medications. It also blocks the effects of estrogen on the breast cancer cells. This medication prevents the growth of breast cancer cells in postmenopausal women.
The active ingredient in the drug is not present in the tablet. The active ingredient is excreted in the urine and the drug is excreted in the faeces.
The active ingredient is excreted in the faeces.
What should I do if I miss a dose?If you miss a dose, take it as soon as you can.
The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser.For the best experience on our site, be sure to turn on Javascript in your browser.
Pleasant taste
Regular Price$8.99 /ucerSpecial Price$12.99
3/25/2021
Arimidex is used to reduce estrogen levels in breast milk. Estrogen is converted into estrogen by the body. It is an androgen which is the primary cause of breast cancer. However, other factors such as diet, hormones, and medical conditions (such as lupus) may play a role in some of the estrogen-related side effects. It is thought to be very effective at reducing the risk of endometrial cancer. The recommended dose is one 2.5mg/day Arimidex, taken orally once a day. Do not take more than what your doctor tells you to take Arimidex. Take Arimidex exactly as your doctor tells you to take it to get the best results.
| Contents | ESTROGEZZA |
|---|---|
| Inquiry | |
| Caveats | ARIMIDEX does not provide any information about the drug and does not work for you. It is an aromatase inhibitor used to reduce estrogen levels in breast milk. Estrogen is converted into estrogen receptor 5 (SER5) in the body. The action of Arimidex is to reduce estrogen levels by reducing production of estrogen in the liver and decreasing the amount of estrogen available in breast milk. This will help to reduce the risk of endometrial and ovarian cancer. It is used to reduce the risk of endometrial and ovarian cancer. It is used to reduce the risk of uterine cancer, which is the most common cancer in women with endometriosis. |
At the recent FDA meeting, researchers analyzed the sales and marketing of arimidex, an anastrozole that helps treat hormone receptor-positive breast cancer. Researchers found that arimidex generated $1.3 billion in sales in the United States, which is nearly five times the $1.4 billion the FDA has estimated. Arimidex is available in tablet form, and is taken orally with or without food. A user-friendly liquid formulation is also available to ensure the drug stays in your system for optimal absorption.
Here's how Arimidex compares to other anastrozole products:
For more detailed information on Arimidex, including potential side effects, side effects, and cost, visit the.
Before using Arimidex, it's essential to follow the instructions provided by your healthcare provider. Your doctor will likely check your body's response to the medication, as the compound can affect how your body responds to the drug.
Before taking Arimidex, you should avoid consuming alcohol or grapefruit juice, as they can increase the risk of side effects. You should also avoid consuming any other medications that contain aromatase inhibitors, as these can increase the risk of side effects. If you have any concerns about Arimidex use, consult your doctor.
Stade de France Pharmacy